secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001651308-25-000131
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84
------------------------------------------------------------------

- Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.
- GAAP net income $94.3M ($0.84 diluted EPS/ADS) vs loss of $120.4M a year ago.
- Non-GAAP diluted EPS $2.25, adjusted income from operations $274.9M (up 467% YoY).
- Free cash flow positive $219.8M vs negative $205.5M in Q2 2024.
- Company expects 20+ R&D milestones in next 18 months across hematology and solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/0001651308-25-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/bgne-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer